AVALIAÇÃO DA ESTABILIDADE DAS ALTERAÇÕES PROMOVIDAS PELO APARELHO REGULADOR DE FUNÇÃO FRÄNKEL-2 NOS ARCOS DENTÁRIOS

O objetivo do presente estudo consistiu em analisar a estabilidade das alterações oclusais em 18 pacientes com má oclusão de Classe II, divisão 1, idade média inicial de 10,77 anos, tratados com o aparelho regulador de função RF-2 durante 18 meses e reavaliados num período de pós-tratamento 7,16 anos, em média. Os 54 modelos de gesso foram avaliados no início do tratamento (T1), no final do tratamento (T2) e decorridos 7,16 anos pós-tratamento (T3). Foram analisadas as alterações transversais e sagitais; o Índice de irregularidade de Little e o Índice de Prioridade de Tratamento (IPT). As alterações ocorridas nos períodos analisados foram verificadas por meio da análise de Variância- ANOVA e, em seguida, pelo teste de comparações múltiplas de Bonferroni, com o valor crítico adotado de 0,05. Os resultados demonstraram que o tratamento com o RF-2 promoveu um aumento transversal estatisticamente significante, tanto no arco dentário superior quanto no inferior, porém, no período pós-tratamento, houve recidiva parcial ou mesmo total deste aumento na maioria das dimensões analisadas. Já o comprimento dos arcos dentários superior e inferior diminuiu durante todo o período avaliado. O Índice de Irregularidade de Little apresentou-se estável durante o tratamento, entretanto aumentou no período pós-tratamento. Além disso, o tratamento com o RF-2 proporcionou uma diminuição estatisticamente significante do IPT, refletindo a eficácia do tratamento realizado uma vez que esta diminuição permaneceu estável no período pós-tratamento. Portanto, o aparelho RF-2 demonstrou ser eficaz na correção dentária da má oclusão de Classe II, divisão 1, com estabilidade dos resultados decorridos 7,16 anos após o tratamento. Porém, em relação ao ganho transversal nos arcos dentários obtido durante o tratamento, houve recidiva parcial ou total de todas as variáveis analisadas.(AU)

AVALIAÇÃO CEFALOMÉTRICA DA ESTABILIDADE DO TRATAMENTO COM O REGULADOR DE FUNÇÃO FRÄNKEL-2

O objetivo desta pesquisa consistiu em comparar as alterações dentárias, esqueléticas e tegumentares promovidas pelo aparelho de Fränkel-2 com um grupo controle, além de observar a estabilidade desses efeitos promovidos pelo tratamento, num período médio de 7,11 anos pós-tratamento. A amostra compreendeu um total de 90 telerradiografias em norma lateral, sendo 54 telerradiografias provenientes de 18 pacientes tratados com o RF-2 avaliados em três fases (T1:início de tratamento;T2: final de tratamento e T3: pós-tratamento) e 36 telerradiografias de 18 pacientes-controle, observados em dois tempos. Para comparação entre os grupos tratado e controle foi utilizado o teste t de Student não pareado. Já para a análise dos valores do grupo tratado nos três tempos (T1, T2 e T3) foi utilizada a Análise de Variância (ANOVA) a um critério e o teste de Tukey (p<0,05). As principais alterações proporcionadas pelo aparelho RF-2 observadas a partir da comparação do grupo tratado com o controle envolveram efeitos mandibulares, principalmente a protrusão e aumento do comprimento mandibular associado com uma rotação horária, que resultou em uma maior altura facial total (N-Me) e ântero-inferior (AFAI), além de suave rotação anti-horária do plano palatino (SN.PP). Os incisivos superiores retruíram e o inferior vestibularizou. Houve uma distalização relativa dos molares superiores juntamente com a diminuição do overjet , desta forma a convexidade do perfil facial tegumentar melhorou. No período pós-tratamento (T3) observou-se uma estabilidade sagital de maxila (SNA) e mandíbula (SNB), das variáveis do padrão facial, da inclinação do incisivo superior, do ângulo nasolabial e do overjet . A mandíbula e a maxila continuaram a crescer no sentido antero-posterior, juntamente com as alturas faciais Houve também a extrusão de incisivos e molares. Já o plano oclusal e o ângulo goníaco diminuíram na fase pós-tratamento.(AU)

COMPARAÇÃO DA EFICIÊNCIA OCLUSAL DO TRATAMENTO ORTOPÉDICO COM O REGULADOR DE FUNÇÃO FRÄNKEL-2 E BIONATOR DE BALTERS POR MEIO DO ÍNDICE PAR

O objetivo deste estudo retrospectivo foi comparar a eficiência oclusal do tratamento ortopédico com os aparelhos funcionais Regulador de Função Fränkel-2 e Bionator de Balters em um estágio de desenvolvimento dental diferente e comparar com um grupo controle. A amostra constituiu-se de 45 registros de documentações, pertencentes ao arquivo do programa de pós-graduação em Odontologia, área de concentração Ortodontia, da Universidade Metodista de São Paulo, com má oclusão inicial de Classe II bilateral, divisão 1, sendo 15 pacientes provenientes do grupo tratados com Bionator (grupo 1) com média de idade incial de 8,56 anos e com 80% dos casos em um estágio de desenvolvimento dental-2 (DS 2), 15 pacientes tratados com RF-2 (grupo 2) com média de idade inicial de 10,71 anos e com 80% dos casos em um estágio de desenvolvimento dental-3 (DS 3), e 15 pacientes controle (grupo 3) com media de idade incial de 10,03 anos e com estágio de desenvolvimento dental compatível com os grupos 1 e 2. Os grupos foram divididos em duas fases, de acordo com o período de avaliação: T1:início de tratamento e T2: final de tratamento, totalizando 90 pares de modelos. As avaliações oclusais foram realizadas em modelos de gesso, utilizando o Índice PAR com auxílio da régua PAR e de um paquímetro digital devidamente calibrado. Para comparação entre os três grupos foi utilizado Análise de Variância a um critério e em seguida o Teste de Tukey. A severidade da má oclusão (PAR Inicial) foi semelhante em ambos os grupos, porém, o PAR final apresentou uma diferença estatisticamente significante onde o percentual de redução do índice PAR para o grupo 1 foi de 20,72%, para o grupo 2 foi de 60,06% e no grupo 3 não houve alteração significante do valor do Índice PAR. O presente estudo conclui que o tratamento da má oclusão de Classe II, 1a divisão é mais eficiente quando iniciado no estágio de desenvolvimento dental 3 (DS 3) do que no estágio de desenvolvimento dental 2 (DS2). Além disso, ressalta-se a importância do uso mais prolongado do aparelho ortopédico, já que os pacientes do grupo 2 apresentaram melhores resultados oclusais.(AU)

AVALIAÇÃO DA ESTABILIDADE DAS ALTERAÇÕES TRANSVERSAIS PROMOVIDAS PELO APARELHO REGULADOR DE FUNÇÃO FRANKEL 2, POR MEIO DE TELERRADIOGRAFIAS POSTEROANTERIORES

O objetivo desta pesquisa constituiu em avaliar, por meio das telerradiografias posteroanteriores, as alterações transversais promovidas pelo aparelho Frankel-2 em pacientes com maloclusão de Classe II, divisão 1, além de verificar a estabilidade das mesmas após um período médio de 7,11 anos pós-tratamento. A amostra compreendeu um total de 45 telerradiografias posteroanteriores provenientes de 15 pacientes tratados com o RF-2, realizadas em três fases: (T1) início do tratamento; (T2) final de tratamento; (T3) pós-tratamento. Foram avaliadas outras 36 telerradiografias posteroanteriores de 18 pacientes não tratados (grupo controle), acompanhados num período correspondente ao tratamento (T1-T2). As telerradiografias foram digitalizadas e foi utilizado o software Radiocef Studio 2 para realizar as mensurações das medidas cefalométricas. Para a comparação entre as alterações ocorridas no grupo tratado e no grupo controle, foi aplicado o teste t não pareado. Já para as modificações nas fases inicial, final e pós-tratamento no grupo tratado, foi empregada a Análise de Variância seguida do teste de comparações múltiplas de Tukey, com o valor crítico de 0,05. Os resultados mostraram que durante o período de tratamento as distâncias intercaninos inferiores e intermolares superiores aumentaram de forma estatisticamente significante. Já as distâncias que representam a largura da cavidade nasal, altura facial inferior, largura mandibular e distância intermolares inferiores não sofreram alterações estatisticamente significantes. No período pós-tratamento, observou-se uma suave redução nas distâncias intercaninos inferiores e intermolares superiores. Porém, considerando-se as alterações ocorridas devido ao crescimento e desenvolvimento transversal dos arcos dentários no período analisado, em que haveria uma redução destas distâncias, provavelmente houve uma estabilidade relativa das alterações dentárias transversais promovidas pelo RF-2. Portanto, pode-se concluir que o RF-2 não possui qualquer efeito esquelético transversal. Contudo, há um aumento das distâncias intermolares superiores e intercaninos inferiores durante o tratamento, que permanece relativamente estável, considerando-se as alterações ocorridas pelo crescimento e desenvolvimento normal dos arcos dentários.

AVALIAÇÃO DO COMPRIMENTO DA COROA CLÍNICA DOS DENTES ÂNTERO-INFERIORES EM PACIENTES TRATADOS COM APARELHO REGULADOR DE FUNÇÃO FRÄNKEL-2

O objetivo do estudo consistiu em verificar uma possível alteração no tamanho da coroa clínica dos dentes ântero-inferiores em 50 indivíduos portadores de má Oclusão de Angle Classe II. A amostra foi dividida em 2 grupos: um grupo tratado com 25 indivíduos (14 do sexo masculino e 11 do feminino) com idade média em T1 (tempo inicial do tratamento) de 11 anos (dp = 9 meses), e em T2 (tempo pós-tratamento) de 12 anos e 7 meses (dp = 7 meses), tratados com o aparelho regulador de função Fränkel-2, durante 18 meses; e, um grupo controle com 25 indivíduos (12 do sexo masculino e 13 do feminino) com idade média em T1 de 10 anos e 3 meses (dp = 11 meses) e em T2 de 12 anos e 1 mês (dp = 11 meses). Os 100 modelos em gesso dos indivíduos foram analisados e comparados em relação ao início e ao término do tratamento por meio de um paquímetro digital, utilizando-se como medida a distância da borda incisal até a porção mais côncava da margem gengival dos incisivos e caninos inferiores. Os dados foram analisados por meio do teste t de Student e teste t pareado. Dentre os seis dentes ântero-inferiores, todos apresentaram aumento significante no grupo tratado, e apenas três dentes (33,42 e 43) apresentaram aumento significante no grupo controle. Já em relação ao grupo tratado e o grupo controle em T2, houve um aumento significante da coroa nos dentes 32, 33 e 43. Houve um aumento estatisticamente significante em apenas dois dentes (31 e 41) em ambos os sexos. Os resultados não demonstraram relevância estatística quando comparados com a alteração do tamanho da coroa no decorrer da idade. Conclui-se que as medidas das coroas clínicas dos dentes diferiram entre os grupos, sendo maior no grupo tratado. O aumento da coroa clinica dos dentes, não esta relacionado somente pela presença de inclinação para vestibular dos mesmo, mas pode ser considerado como multifatorial.

Targeted delivery of a novel group of site-directed transglutaminase inhibitors to the liver using liposomes:a new approach for the potential treatment of liver fibrosis

Liver fibrosis and its end-stage disease cirrhosis are a main cause of mortality and morbidity worldwide. Thus far, there is no efficient pharmaceutical intervention for the treatment of liver fibrosis. Liver fibrosis is characterized by excessive accumulation of the extracellular matrix (ECM) proteins. Transglutaminase (TG)-mediated covalent cross-linking has been implicated in the stabilization and accumulation of ECM in a number of fibrotic diseases. Thus, the use of tissue TG2 inhibitors has potential in the treatment of liver fibrosis. Recently, we introduced a novel group of site-directed irreversible specific inhibitors of TGs. Here, we describe the development of a liposome-based drug-delivery system for the site-specific delivery of these TG inhibitors into the liver. By using anionic or neutral-based DSPC liposomes, the TG inhibitor can be successfully incorporated into these liposomes and delivered specifically to the liver. Liposomes can therefore be used as a potential carrier system for site-specific delivery of the TG2 inhibitors into the liver, opening up a potential new avenue for the treatment of liver fibrosis and its end-stage disease cirrhosis.

Transglutaminase inhibition reduces fibrosis and preserves function in experimental chronic kidney disease

Progressive tissue fibrosis is involved in debilitating diseases that affect organs including the lungs, liver, heart, skin, and kidneys. Recent evidence suggests that tissue transglutaminase, an enzyme that crosslinks proteins, may be involved in tissue fibrosis by crosslinking and stabilizing the extracellular matrix or by recruiting and activating the large latent transforming growth factor (TGF)-β1 complex. We treated rats that had undergone 5/6-nephrectomy with two different irreversible inhibitors of transglutaminase and found that both prevented a decline in kidney function and reduced the development of glomerulosclerosis and tubulointerstitial fibrosis by up to 77% and 92%, respectively. Treatment reduced the accumulation of collagen I and collagen III, with the primary mechanism of action being direct interference with the crosslinking of extracellular matrix rather than altered regulation of TGFβ1. We conclude that inhibition of transglutaminase offers a potential therapeutic option for chronic kidney disease and other conditions that result from tissue fibrosis. Copyright © 2007 by the American Society of Nephrology.

Studies of the nature of Burkholderia cepacia in cystic fibrosis

Burkholderia cepacia is an opportunistic pathogen that colonises of the lungs of cystic fibrosis (CF) patients, with a frequently fatal outcome. Antibiotic resistance is common and highly transmissible epidemic strains have been described in the UK. 37 B. cepacia isolates from clinical and botanical sources were characterised via metabolic capabilities, antibiotic sensitivity, fatty acid methyl ester (FAME) profiles restriction digest analysis of chromosomal DNA by pulsed-gel electrophoresis (PFGE) (with the use of two separate restriction enzymes) and outer membrane protein (OMP) profiles. This revealed isolates of the UK CF epidemic strain to form a distinct group with a specific OMP profile. Cluster analysis of PFGE and FAME profiles revealed the species Burkholderia gladioli and Burkholderia vietnamiensis to be more closely related to each other and to laboratory strains of B. cepacia than to the CF epidemic strain considered a member of the latter species. The epidemic strain of B. cepacia may therefore be worthy of species definition in its own right. All the strains studied showed a high level of resistance to antibiotics, including the carbapenems. Considering this, carbapenemase production by isolates of B. cepacia was investigated. A metallo-β-lactamase from a clinical strain of B. cepacia was isolated and partially purified of using Cibacron blue F3GA-coupled agarose. The resulting preparation showed a single band of β-lactamase activity (pI 8.45) after analytical isoelectric focusing. The enzyme was particularly effective in the hydrolysis of imipenem. Meropenem, biapenem, cephaloridine, ceftazidime, benzylpenicillin, ampicillin and carbenicillin were hydrolysed at a lower rate. An unusual inhibition profile was noted. Inhibition by the metal ion chelators ethylene diamine tetra acetic acid and o-phenanthroline was reversed by addition of zinc, indicating a metallo-enzyme, whilst >90% inhibition was attainable with 0.1mM concentrations of tazobactam and clavulanic acid. A study of 8 other clinical isolates showed an enzyme of pI 8.45 to be present and inducible by imipenem in each case. This enzyme was assigned PCM-I (Pseudomonas cepacia metalloenzyme I).

Liposomes as carriers for polymyxins in the treatment of cystic fibrosis lung infections

Cystic fibrosis (CF) is the most common autosomal recessive disorder affecting Caucasian populations. The pathophysiology of this disorder predisposes the lungs of affected patients to chronic infection, typically by Pseudomonas aeruginosa, which is the main cause of morbidity and mortality. Recently, attention has focused on aerosolised polymyxins, which are given prophylactically in an effort to limit infection and subsequent lung damage. This class of antimicrobial compounds is highly active against P. aeruginosa and possess the advantage that resistance rarely develops. However, the rapid lung clearance of antibiotics is a well documented phenomenon and it was postulated that polymyxin treatment could be further improved by liposomal encapsulation. As part of the development of liposomal polymyxin B, analytical methodology (radiolabelling, HPLC and protein assay) applicable to liposomal formulations was established. Liposomes were prepared by the dehydration-rehydration method and encapsulation efficiencies were determined for a number of phospholipid compositions. Vesicles were characterised with respect to size, zeta potential, morphology and release characteristics. The surface hydrophobicity of vesicles was quantified by hydrophobic interaction chromatography and it was found that this method produced comparable results to techniques conventionally used to assess this property. In vivo testing of liposomal polymyxins demonstrated that encapsulation successfully prevented the rapid pulmonary clearance of PXB. Antimicrobial activity of liposomal formulations was quantified and found to be dependent on both the vesicle surface characteristics and their release profile. Investigation of the interaction of PXB with lipopolysaccharide was undertaken and results demonstrated that PXB caused significant structural distortion of the lipid A region. This may be sufficient to abrogate the potentiating action of LPS in the inflammatory cascade.

Studies on bacterial lung infections in cystic fibrosis

The major cause of death in CF is a continuous inflammation of the lungs colonised with Pseudomonas aeruginosa and occasionally also with Burkholderia cepacia. A combination of serum IgG to LPS and serum PCT levels were found to be good markers for detection of early colonisation with P. aeruginosa. Colomycin sulphomethate (colistin E) is one of the antibiotics used to treat P. aeruginosa infections in CF. Electrophoretic methods were developed to monitor the rate of conversion of colomycin sulphomethate to the active form of the drug. Antimicrobial activity towards P. aeruginosa was generated as the sulphomethate substituents were released. Clinical resistance of P. aeruginosa to colomycin is rare, but a number of isolates have been isolated. Twelve colomycin-resistant clinical isolates were investigated to determine the mechanism of resistance. It was found that the low level of resistance was due to over expression of outer membrane protein H (OprH) in 5 isolates. A novel mechanism of resistance involving modification of the phosphate groups in LPS was identified in one of the isolates. Drugs which reduce inflammation in infected CF lungs would be of great advantage for therapy. Reducing inflammation would preserve the lung function and increase the quality of life for CF patients. Antibiotics like tetracyclines, macrolides and polymyxins were tested for their potential anti-inflammatory effects using cultured human monocytic (U937) cells which secrete the pro-inflammatory cytokines IL1- and TNF- in response to LPS from P. aeruginosa and B. cepacia. It was found that tetracyclines, and especially doxycycline, are good inhibitors of cytokine release by U937 cells and therefore could reduce the inflammatory cascade.

The surface of Pseudomonas aeruginosa in cystic fibrosis lung infection

Chronic experimental lung infection in rats was induced by intratracheal inoculation of agar beads containing Pseudomonas aeruginosa. Bacteria were recovered directly without subculture from the lungs of rats at 14 days post-infection and the outer membrane (OM) antigens were studied. The results indicated that bacteria grew under iron-restricted conditions as revealed by the expression of several iron-regulated membrane proteins (IRMPs) which could also be observed when the isolate was grown under iron-depleted conditions in laboratory media. The antibody response to P. aeruginosa OM protein antigens was investigated by immunoblotting with serum and lung fluid from infected rats. These fluids contained antibodies to all the major OM proteins, including the IRMPs, and protein H1. Results obtained using immunoblotting and enzyme-linked immunosorbent assay indicated that lipopolysaccharide (LPS) was the major antigen recognised by antibodies in sera from infected rats. The animal model was used to follow the development of the immune response to P. aeruginosa protein and LPS antigens. Immunoblotting was used to investigate the antigens recognised by antibodies in sequential serum samples. An antibody response to the IRMPs and OM proteins D, E, G and H1 and alao to rough LPS was detected as early as 4 days post-infection. Results obtained using immunoblotting and crossed immunoelectrophoresis techniques indicated that there was a progressive increase in the number of P. aeruginosa antigens recognised by antibodies in these sera. Both iron and magnesium depletion influenced protein H1 production. Antibodies in sera from patients with infections due to P. aeruginosa reacted with this antigen. Results obtained using quantitative gas-liquid chromatographic analysis indicated that growth phase and magnesium and iron depletion also affected the amount of LPS fatty acids, produced by P. aeruginosa. The silver stained SDS-polyacrylamide gels of proteinase K digested whole cell lysates of P. aeruginosa indicated that the O-antigen and core LPS were both affected by growth phase and specific nutrient depletion.

Local and systemic delivery of a novel group of inhibitors of transglutaminase enzyme: A potential approach for treating of catheter-related complications and liver fibrosis

The present thesis investigates targeted (locally and systemically) delivery of a novel group of inhibitors of enzyme transglutaminases (TGs). TGs are a widely distributed group of enzymes that catalyse the formation of isopeptide bonds between the y-carboxamide group of protein-bound glutamines and the a-amino group of protein-bound lysines or polyamines. The first group of the novel inhibitors tested were the tluorescently labelled inhibitors of Factor XIIIa (FXIIIa). These small, non-toxic inhibitors have the potential to prevent stabilisation of thrombi by FXIIIa and consequently increase the natural rate of thrombolysis, in addition it reduces staphylococcal colonisation of catheters by inhibiting their FXIIIa¬mediated cross-linking to blood clot proteins on the central venous catheter (CVCs) surface. The aim of this work was to incorporate the FXIIIa inhibitor either within coating of polyurethane (PU) catheters or to integrate it into silicone catheters, so as to reduce the incidence of thrombotic occlusion and associated bacterial infection in CVCs. The initial work focused on the incorporation of FXIIIa inhibitors within polymeric coatings of PU catheters. After defining the key characteristics desired for an effective polymeric-coating, polyvinylpyrrolidone (PVP), poly(lactic-co-glycolic acid) (PLGA) or their combination were studies as polymers of choice for coating of the catheters_ The coating was conducted by dip-coating method in a polymer solution containing the inhibitor. Upon incubation of the inhibitor-and polymer-coated strips in buffer, PVP was dissolved instantly, generating fast and significant drug release, whilst PLGA did not dissolve, yielding a slow and an insufficient amount of drug release. Nevertheless, the drug release profile was enhanced upon employing a blend solution of PVP and PLGA. The second part of the study was to incorporate the FXIIIa inhibitor into a silicone elastomer; results demonstrated that FXIIIa inhibitor can be incorporated and released from silicone by using citric acid (CA) and sodium bicarbonate (SB) as additives and the drug release rate can be controlled by the amount of incorporated additives in the silicone matrix. Furthermore, it was deemed that the inhibitor was still biologically active subsequent to being released from the silicone elastomer strips. Morphological analysis confirmed the formation of channels and cracks inside the specimens upon the addition of CA and SB. Nevertheless, the tensile strength, in addition to Young's modulus of silicone elastomer strips, decreased constantly with an increasing amount of amalgamated CA/ SB in the formulations. According to our results, incorporation of FXIIIa inhibitor into catheters and other medical implant devices could offer new perspectives in preventing bio-material associated infections and thrombosis. The use of tissue transglutaminase (T02) inhibitor for treating of liver fibrosis was also investigated. Liver fibrosis is characterized by increased synthesis and decreased degradation of the extracellular matrix (ECM). Transglutaminase-mediated covalent cross-linking is involved in the stabilization of ECM in human liver fibrosis. Thus, TG2 inhibitors may be used to counteract the decreased degradation of the ECM. The potential of a liposome based drug delivery system for site specific delivery of the fluorescent TG2 inhibitor into the liver was investigated; results indicated that the TG2 inhibitor can be successfully integrated into liposomes and delivered to the liver, therefore demonstrating that liposomes can be employed for site-specific delivery of TG2 inhibitors into the liver and TG2 inhibitor incorporating liposomes could offer a new approach in treating liver fibrosis and its end stage disease cirrhosis.

Development of a multicellular co-culture model of normal and cystic fibrosis human airways in vitro

Cystic fibrosis (CF) is the most common lethal inherited disease among Caucasians and arises due to mutations in a chloride channel, called cystic fibrosis transmembrane conductance regulator. A hallmark of this disease is the chronic bacterial infection of the airways, which is usually, associated with pathogens such as Pseudomonas aeruginosa, S. aureus and recently becoming more prominent, B. cepacia. The excessive inflammatory response, which leads to irreversible lung damage, will in the long term lead to mortality of the patient at around the age of 40 years. Understanding the pathogenesis of CF currently relies on animal models, such as those employing genetically-modified mice, and on single cell culture models, which are grown either as polarised or non-polarised epithelium in vitro. Whilst these approaches partially enable the study of disease progression in CF, both types of models have inherent limitations. The overall aim of this thesis was to establish a multicellular co-culture model of normal and CF human airways in vitro, which helps to partially overcome these limitations and permits analysis of cell-to-cell communication in the airways. These models could then be used to examine the co-ordinated response of the airways to infection with relevant pathogens in order to validate this approach over animals/single cell models. Therefore epithelial cell lines of non-CF and CF background were employed in a co-culture model together with human pulmonary fibroblasts. Co-cultures were grown on collagen-coated permeable supports at air-liquid interface to promote epithelial cell differentiation. The models were characterised and essential features for investigating CF infections and inflammatory responses were investigated and analysed. A pseudostratified like epithelial cell layer was established at air liquid interface (ALI) of mono-and co-cultures and cell layer integrity was verified by tight junction (TJ) staining and transepithelial resistance measurements (TER). Mono- and co-cultures were also found to secrete the airway mucin MUC5AC. Influence of bacterial infections was found to be most challenging when intact S. aureus, B. cepacia and P. aeruginosa were used. CF mono- and co-cultures were found to mimic the hyperinflammatory state found in CF, which was confirmed by analysing IL-8 secretions of these models. These co-culture models will help to elucidate the role fibroblasts play in the inflammatory response to bacteria and will provide a useful testing platform to further investigate the dysregulated airway responses seen in CF.

Defective peroxisomal proliferators activated receptor gamma activity due to dominant-negative mutation synergizes with hypertension to accelerate cardiac fibrosis in mice

Aims: Humans with inactivating mutations in peroxisomal proliferators activated receptor gamma (PPAR?) typically develop a complex metabolic syndrome characterized by insulin resistance, diabetes, lipodystrophy, hypertension, and dyslipidaemia which is likely to increase their cardiovascular risk. Despite evidence that the activation of PPAR? may prevent cardiac fibrosis and hypertrophy, recent evidence has suggested that pharmacological activation of PPAR? causes increased cardiovascular mortality. In this study, we investigated the effects of defective PPAR? function on the development of cardiac fibrosis and hypertrophy in a murine model carrying a human dominant-negative mutation in PPAR?. Methods and results: Mice with a dominant-negative point mutation in PPAR? (P465L) and their wild-type (WT) littermates were treated with either subcutaneous angiotensin II (AngII) infusion or saline for 2 weeks. Heterozygous P465L and WT mice developed a similar increase in systolic blood pressure, but the mutant mice developed significantly more severe cardiac fibrosis to AngII that correlated with increased expression of profibrotic genes. Both groups similarly increased the heart weight to body weight ratio compared with saline-treated controls. There were no differences in fibrosis between saline-treated WT and P465L mice. Conclusion: These results show synergistic pathogenic effects between the presence of defective PPAR? and AngII-induced hypertension and suggest that patients with PPAR? mutation and hypertension may need more aggressive therapeutic measures to reduce the risk of accelerated cardiac fibrosis. © The Author 2009.

Free secretory component from cystic fibrosis sputa displays the cystic fibrosis glycosylation phenotype

Secretory IgA contributes to humoral defense mechanisms against pathogens targeting mucosal surfaces, and secretory component (SC) fulfills multiple roles in this defense. The aims of this study were to quantify total SC and to analyze the form of free SC in sputa from normal subjects, subjects with asthma, and subjects with cystic fibrosis (CF). Significantly higher levels of SC were detected in CF compared with both other groups. Gel filtration chromatography revealed that SC in CF was relatively degraded. Free SC normally binds interleukin (IL)-8 and inhibits its function. However, in CF sputa, IL-8 binding to intact SC was reduced. Analysis of the total carbohydrate content of free SC signified overglycosylation in CF compared with normal subjects and subjects with asthma. Monosaccharide composition analysis of free SC from CF subjects revealed overfucosylation and undersialylation, in agreement with the reported CF glycosylation phenotype. SC binding to IL-8 did not interfere with the binding of IL-8 to heparin, indicating distinct binding sites on IL-8 for negative regulation of function by SC and heparin. We suggest that defective structure and function of SC contribute to the characteristic sustained inflammatory response in the CF airways.